Intra-Cellular Therapies, Inc.

Two companies of similar economic scale and each with its own troubled financial history revealed plans to merge on 13 March, as privately held Mallinckrodt and publicly traded Endo will combine into

Entering 2025, biopharma industry observers expected an uptick of merger-and-acquisition activity, coming off a 2024 that saw some historic lows for such activity. Hopes were raised with some sizeab

Despite notable advancements in Alzheimer’s disease treatment during the last five years, the therapeutic area remains a complex and uncertain area for drug developers. Approvals for the first disease

With many big pharmas anxious to fill their portfolios with new commercial sellers and biotechs running low on cash, 2025 is expected to be a big year for deals and M&A across the biopharma sector